Suppr超能文献

中国武汉新冠肺炎重症监护病房患者的胰腺酶升高:一项回顾性研究

Elevated Pancreatic Enzymes in ICU Patients With COVID-19 in Wuhan, China: A Retrospective Study.

作者信息

Ding Peili, Song Bin, Liu Xuelin, Fang Xing, Cai Hongliu, Zhang Dingyu, Zheng Xia

机构信息

Department of Critical Care Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Department of Tuberculosis and Respiratory Disease, Jinyintan Hospital, Wuhan, China.

出版信息

Front Med (Lausanne). 2021 Aug 17;8:663646. doi: 10.3389/fmed.2021.663646. eCollection 2021.

Abstract

Pancreatic enzyme elevation has been reported in patients with COVID-19 during the pandemic. However, with the shortage of medical resources and information, several challenges are faced in the examination and treatment of this condition in COVID-19 patients. There is little information on whether such condition is caused by pancreatic injury, and if this is a warning sign of life threatening complications like multiple organ failure in patients. The objective of this study is to explore the relationship between elevated pancreatic enzymes and the underlying risk factors during the management of COVID-19 patients. A total of 55 COVID-19 patients admitted to the intensive care unit (ICU) of Wuhan Jinyintan hospital from January 1 to March 30, 2020 were enrolled in this study. All participants underwent transabdominal ultrasound imaging to assess their pancreas. Out of the 55 patients, three patients had pancreatitis, 29 (52.7%) with elevated pancreatic enzymes, and 23 (41.8%) without. The most common symptoms of patients with COVID-19 were fever and cough. There was no statistical difference in most baseline characteristics except myalgia on admission. Compared with those having normal enzyme levels, patients with elevated pancreatic enzymes had higher rates of mortality (79.3 vs. 52.2%; = 0.038), and lower rates of discharge (20.7 vs. 47.8%; = 0.038). Patients with elevated enzymes had higher incidence of mechanical ventilation ( = 0.004) and kidney injury ( = 0.042) than patients without elevated pancreatic enzymes. The results of multivariable logistic analysis showed that the odds ratio were 10.202 ( = 0.002) for mechanical ventilation and 7.673 ( = 0.014) for kidney injury with the elevated enzymes vs. the normal conditions. The findings show that the incidences of pancreatic enzymes elevation are not low in critical COVID-19 patients and only a few of them progressed to acute pancreatitis (AP). Increased pancreatic enzymes levels is associated with poor prognosis in COVID-19 patients. In addition, the kidney injury and oxygenation degradation are associated with the pancreatic enzymes elevation in COVID-19 patients.

摘要

在疫情期间,已有报告称新冠病毒疾病(COVID-19)患者出现胰腺酶升高的情况。然而,由于医疗资源和信息短缺,COVID-19患者这一病症的检查和治疗面临诸多挑战。关于这种情况是否由胰腺损伤引起,以及这是否是患者出现多器官功能衰竭等危及生命并发症的警示信号,目前几乎没有相关信息。本研究的目的是探讨COVID-19患者管理期间胰腺酶升高与潜在风险因素之间的关系。本研究纳入了2020年1月1日至3月30日期间收治于武汉金银潭医院重症监护病房(ICU)的55例COVID-19患者。所有参与者均接受了经腹超声成像以评估其胰腺情况。在这55例患者中,3例患有胰腺炎,29例(52.7%)胰腺酶升高,23例(41.8%)胰腺酶未升高。COVID-19患者最常见的症状是发热和咳嗽。除入院时肌痛外,大多数基线特征无统计学差异。与酶水平正常的患者相比,胰腺酶升高的患者死亡率更高(79.3%对52.2%;P = 0.038),出院率更低(20.7%对47.8%;P = 0.038)。酶升高的患者机械通气发生率(P = 0.004)和肾损伤发生率(P = 0.042)高于胰腺酶未升高的患者。多变量逻辑分析结果显示,与酶水平正常的情况相比时,酶升高的患者机械通气的比值比为10.202(P = 0.002),肾损伤的比值比为7.673(P = 0.014)。研究结果表明,重症COVID-19患者中胰腺酶升高的发生率不低,其中只有少数进展为急性胰腺炎(AP)。胰腺酶水平升高与COVID-19患者的不良预后相关。此外,肾损伤和氧合恶化与COVID-19患者的胰腺酶升高有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca89/8415839/dae13554141c/fmed-08-663646-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验